⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Catherine Lee Ziyue Karen Jiang Simon Planken Lisa K. Manzuk Roberto Ortiz Michael Hall Kavon Noorbehesht Sripad Ram Timothy Affolter Gabriel E. Troche Nathan T. Ihle Theodore Johnson Youngwook Ahn Manfred Kraus Anand Giddabasappa

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment in the PET imaging cohort of animals

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875224ec https://doi.org/10.1158/1535-7163.27035959

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
2Supplementary Figure S3 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
3Supplementary Figure S3 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
4Supplementary Figure S5 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
5Supplementary Figure S5 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
6Supplementary Figure S7 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
7Supplementary Figure S7 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024
8Supplementary Figure S1 from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer2024